Niagen Bioscience (NASDAQ:NAGE – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.
Risk and Volatility
Niagen Bioscience has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.
Earnings & Valuation
This table compares Niagen Bioscience and Viridian Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Niagen Bioscience | $129.42 million | 3.13 | $17.38 million | $0.20 | 25.30 |
| Viridian Therapeutics | $70.85 million | 40.88 | -$342.60 million | ($3.29) | -8.61 |
Niagen Bioscience has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
15.4% of Niagen Bioscience shares are held by institutional investors. 9.4% of Niagen Bioscience shares are held by insiders. Comparatively, 1.6% of Viridian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Niagen Bioscience and Viridian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Niagen Bioscience | 13.43% | 21.10% | 14.92% |
| Viridian Therapeutics | -483.57% | -83.25% | -50.38% |
Analyst Ratings
This is a breakdown of current ratings and target prices for Niagen Bioscience and Viridian Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Niagen Bioscience | 0 | 1 | 3 | 0 | 2.75 |
| Viridian Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
Niagen Bioscience presently has a consensus price target of $16.00, suggesting a potential upside of 216.21%. Viridian Therapeutics has a consensus price target of $42.43, suggesting a potential upside of 49.71%. Given Niagen Bioscience’s higher possible upside, research analysts clearly believe Niagen Bioscience is more favorable than Viridian Therapeutics.
Summary
Niagen Bioscience beats Viridian Therapeutics on 11 of the 14 factors compared between the two stocks.
About Niagen Bioscience
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
About Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
